期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 15, 期 7, 页码 913-925出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2014.902446
关键词
Alzheimer's disease; behavior; cognition; language; memantine; outpatients
资金
- Daiichi Sankyo Co., Ltd.
- Novartis
- Takeda
- Ono Pharmaceutical Co., Ltd
- Janssen Pharmaceuticals, Inc.
- Meiji Seika Pharma Co., Ltd
- Mochida Pharmaceutical Co., Ltd
- GlaxoSmithKline
- Pfizer
- Shionogi Co., Ltd
- Eli Lilly
- Boehringer-Ingelheim
- Toyama Chemical Co., Ltd
- Astellas Pharma, Inc.
- Dainippon Sumitomo Pharma Co., Ltd
- Eisai Co., Ltd
- Mitsubishi Tanabe Pharma
- Otsuka Pharmaceutical Co., Ltd
- Daiichi Sankyo Co., Ltd
- Johnson Johnson
- Grants-in-Aid for Scientific Research [24591717] Funding Source: KAKEN
Background: With the increase in the aging population, there is a pressing need to provide effective treatment options for individuals with Alzheimer's disease (AD). Memantine is an N-methyl-D-aspartate receptor antagonist used to treat AD in > 80 countries worldwide, and studies in the USA and Europe have shown it to be effective in improving language deficits; however, there are currently no data on language improvements in Japanese patients treated with memantine. Objectives: To clarify the efficacy and safety of memantine in Japanese outpatients with moderate to severe AD, using a pooled analysis of two multicenter randomized placebo-controlled trials, a phase 2 dose-finding study and a phase 3 study. Results: The final analysis comprised 633 patients (318 receiving memantine and 315 placebo). Memantine produced better outcomes in terms of Severe Impairment Battery-Japanese version, Clinician's Interview-Based Impression of Change plus-Japanese version, Behavioral Pathology in AD Rating Scale, and language scores, versus placebo. The overall incidence of adverse events and adverse reactions was similar between groups. Conclusion: In this pooled analysis of Japanese patients, memantine achieved better outcomes than placebo in terms of cognition, including attention, praxis, visuospatial ability and language, and behavioral and psychological symptoms, including activity disturbances and aggressiveness.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据